Literature DB >> 12951060

Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line.

Yolande Pengetnze1, Mary Steed, Katherine F Roby, Paul F Terranova, Christopher C Taylor.   

Abstract

The vast majority of ovarian cancers originate in the ovarian surface epithelium. Unfortunately, there is a lack of appropriate animal models for ovarian cancer research. Spontaneously transformed mouse ovarian surface epithelial cells may provide a faithful animal model for human ovarian cancer. One such cell line (ID8) has been partially characterized. ID8 cells demonstrate constitutive Src tyrosine kinase activation with resulting phosphatidylinositol-3-kinase activation and Akt and forkhead phosphorylation. In addition, focal adhesion kinase is constitutively phosphorylated at tyrosine 925, a Src phosphorylation site, resulting in increased Ras activation. These features are common to human ovarian cancer cell lines. Inhibition of Src enhances the cell killing effects of both paclitaxel and cisplatinum. Finally, Src inhibition restores sensitivity of a drug resistant ID8 cell line. The ID8 mouse ovarian cancer cell line presents new opportunities to study ovarian cancer progression and pre-therapeutic trials in an immune competent background.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12951060     DOI: 10.1016/j.bbrc.2003.08.012

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  36 in total

Review 1.  Investigational agents in development for the treatment of ovarian cancer.

Authors:  Shannon N Westin; Thomas J Herzog; Robert L Coleman
Journal:  Invest New Drugs       Date:  2012-06-04       Impact factor: 3.850

2.  Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer.

Authors:  Feng Su; Kathy R Kozak; Satoshi Imaizumi; Feng Gao; Malaika W Amneus; Victor Grijalva; Carey Ng; Alan Wagner; Greg Hough; Gina Farias-Eisner; G M Anantharamaiah; Brian J Van Lenten; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

3.  Targeting SRC in mucinous ovarian carcinoma.

Authors:  Koji Matsuo; Masato Nishimura; Justin N Bottsford-Miller; Jie Huang; Kakajan Komurov; Guillermo N Armaiz-Pena; Mian M K Shahzad; Rebecca L Stone; Ju Won Roh; Angela M Sanguino; Chunhua Lu; Dwight D Im; Neil B Rosenshien; Atsuko Sakakibara; Tadayoshi Nagano; Masato Yamasaki; Takayuki Enomoto; Tadashi Kimura; Prahlad T Ram; Kathleen M Schmeler; Gary E Gallick; Kwong K Wong; Michael Frumovitz; Anil K Sood
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

4.  Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.

Authors:  Deanna Teoh; Tina A Ayeni; Jennifer M Rubatt; David J Adams; Lisa Grace; Mark D Starr; William T Barry; Andrew Berchuck; Susan K Murphy; Angeles Alvarez Secord
Journal:  Gynecol Oncol       Date:  2011-01-03       Impact factor: 5.482

5.  Simultaneous expression of caveolin-1 and E-cadherin in ovarian carcinoma cells stabilizes adherens junctions through inhibition of src-related kinases.

Authors:  Silvia Miotti; Antonella Tomassetti; Ileana Facetti; Elena Sanna; Valeria Berno; Silvana Canevari
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

Review 6.  Src family kinases and paclitaxel sensitivity.

Authors:  Xiao-Feng Le; Robert C Bast
Journal:  Cancer Biol Ther       Date:  2011-08-15       Impact factor: 4.742

7.  Development of a syngeneic mouse model of epithelial ovarian cancer.

Authors:  Bridget A Quinn; Fang Xiao; Laura Bickel; Lainie Martin; Xiang Hua; Andres Klein-Szanto; Denise C Connolly
Journal:  J Ovarian Res       Date:  2010-10-19       Impact factor: 4.234

Review 8.  Oncogenes associated with drug resistance in ovarian cancer.

Authors:  Xia Liu; Yutao Gao; Yi Lu; Jian Zhang; Li Li; Fuqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-06       Impact factor: 4.553

9.  Src-Induced cisplatin resistance mediated by cell-to-cell communication.

Authors:  Elizabeth Peterson-Roth; Cathleen M Brdlik; Peter M Glazer
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

10.  Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.

Authors:  Scott Kopetz; Donald P Lesslie; Nikolas A Dallas; Serk I Park; Marjorie Johnson; Nila U Parikh; Michael P Kim; James L Abbruzzese; Lee M Ellis; Joya Chandra; Gary E Gallick
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.